Novartis AG vs Prospect Capital Corporation — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Prospect Capital Corporation trades at $2.17 (market cap $1.12B). The key difference: Novartis AG is far larger — about 259.2× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (22.42%). Which is the better fit depends on your goals.
| NVS | PSEC | |
|---|---|---|
Market Cap | $290.25B | $1.12B |
Sector | Health | Financials |
52-Week High | $168.62 | $3.47 |
52-Week Low | $113.50 | $2.15 |
Enterprise Value | $330.27B | — |
Dividend Yield | 3.17% | 22.42% |
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →